Oral Communications: Investigator-led clinical and scientific research

Feb 4, 2026 — 11:00 am - 12:00 PM
The Auditorium

Oral Communication

Moderator:

Roger PRESTON, Ana BOBAN

Interventions

11:00 AM11:10 AM

Clinical characteristics of Glanzmann thrombasthenia – First results from the Glanzmann Thrombasthenia Natural History Study

11:10 AM11:20 AM

MRI-Based Assessment of Joint Outcomes in Children with Severe Hemophilia A on Emicizumab Prophylaxis: A Prospective Observational Study

Laila SherifHoffman La Roche Egypt

11:20 AM11:30 AM

Reference Values for the Haemophilia Joint Health Score in Patients with Severe Haemophilia derived from the Canadian Bleeding Disorder Registry

Khang NguyenMcMaster University

11:30 AM11:40 AM

A Novel Genetic Classification of Inhibitor Risk for F8 Nonsense Mutations Based on Immunogenic Profiling of Ribosomal Readthrough in EAHAD database

Maria Francesca TestaUniversità di Ferrara

11:40 AM11:50 AM

Long-term results of patients with acquired haemophilia A in the era of emicizumab

11:50 AM12:00 PM

Update on inhibitor development for individual FVIII concentrates in PUPs with severe hemophilia A in the PedNet registry.